A Study of Verutex (Fusidic Acid), Eritex (Erythromycin) and Fisiogel in the Management of Tarceva-Associated Rash.
Status:
Completed
Trial end date:
2012-06-01
Target enrollment:
Participant gender:
Summary
This 3 arm study will compare the efficacy and safety of three different dermatological
creams designed for prophylaxis of skin rash associated with Tarceva treatment in patients
with locally advanced or metastatic non-small cell lung cancer. Eligible patients who have
recently started Tarceva treatment will be randomized to one of 3 groups, to receive daily
treatment with Verutex, Eritex or Fisiogel cream for 30 days, and the incidence and severity
of skin rash will be assessed. The anticipated time on study treatment is <3 months, and the
target sample size is 100-500 individuals.